NAV
17.56(-0.66%)Fund Size (CR)
₹1,896.11Expense Ratio
0.88Scheme Type
Active FundValue Research
Min. investment
₹100Minimum Additional Investment
₹100Minimum SIP Investment
₹100Minimum Withdrawal
₹100Exit Load
1%Return Since Launch
32.45%
- 3M
- 6M
- 1Y
- 3Y
- All
Basic Details
Scheme Manager
Nikhil Mathur
Bench Mark
BSE Healthcare TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | 6 October 2025 | 10129.49 | 1.29% | - | 0.41% | 119/920 |
| 1 Month | 12 September 2025 | 9899.21 | -1.01% | - | 0.30% | 788/916 |
| 3 Month | 11 July 2025 | 10072.36 | 0.72% | - | 1.34% | 455/880 |
| 6 Month | 11 April 2025 | 11275.59 | 12.76% | - | 14.80% | 462/860 |
| 1 Year | 11 October 2024 | 10650.64 | 6.51% | 6.51% | -0.57% | 123/756 |
| 3 Year | - | - | - | - | - | -/- |
| 5 Year | - | - | - | - | - | -/- |
| Since Inception | 4 October 2023 | 17679.00 | 76.79% | 32.45% | 13.54% | 7/920 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | 4 November 2024 | 1,20,000 | 126646.62 | 5.54% | 5.54% |
| 3 Year | - | - | - | - | - |
| 5 Year | - | - | - | - | - |
| 10 Year | - | - | - | - | - |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
- Investment type
- Scheme based
- SIP
- Lumpsum
Invested Amount
₹25,000
Estimated Returns
₹19,059
76%
Returns
Future value of your investment
₹44,059
Risk Ratios
4.96%
Standard Deviation
0.78%
Beta
1.59%
Sharpe Ratio
0.04%
Treynor's Ratio
21.55%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 10.47% | 1244634 | 198.43 | Equity | Pharmaceuticals |
| Divi's Lab. | 7.76% | 258490 | 147.07 | Equity | Pharmaceuticals |
| Glenmark Pharma. | 6.93% | 672796 | 131.38 | Equity | Pharmaceuticals |
| Lupin | 6.84% | 678274 | 129.64 | Equity | Pharmaceuticals |
| Alkem Lab | 5.94% | 207521 | 112.58 | Equity | Pharmaceuticals |
| Max Healthcare | 4.66% | 791979 | 88.28 | Equity | Healthcare |
| Ipca Labs. | 4.50% | 637260 | 85.33 | Equity | Pharmaceuticals |
| Cipla | 4.32% | 544343 | 81.83 | Equity | Pharmaceuticals |
| Torrent Pharma. | 3.81% | 200598 | 72.28 | Equity | Pharmaceuticals |
| Krishna Institu. | 3.64% | 984676 | 68.94 | Equity | Healthcare |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Direct (G) | 1896.11 | -1.01% | 0.72% | 12.76% | 6.51% | - | |
| Nippon India Taiwan Equity Fund - Direct (G) | 406.67 | -0.23% | 22.00% | 82.69% | 41.91% | 42.01% | |
| Nippon India Taiwan Equity Fund - Direct (IDCW) | 406.67 | -0.23% | 22.00% | 82.69% | 41.91% | 42.01% | |
| Aditya Birla SL International Equity Fund - Direct (G) | 266.19 | -0.28% | 7.78% | 28.88% | 26.05% | 19.55% | |
| Aditya Birla SL International Equity Fund - Direct (IDCW) | 266.19 | -0.28% | 7.78% | 28.88% | 26.05% | 19.55% | |
| Franklin Asian Equity Fund - Direct (G) | 279.13 | 4.59% | 11.90% | 32.68% | 16.44% | 15.74% |
List of Schemes under HDFC Mutual Fund
News
HDFC Mutual Fund announces change in fund manager under its schemes
HDFC Mutual Fund has announced change in fund manager under the following schemes, With effect from 01 October 2025.Change in Fund Manager:
Scheme Name Existing Fund Managers Revised Fund Managers HDFC Liquid Fund* Mr. Anupam Joshi and Mr. Swapnil Jangam Mr. Rohan Pillai and Mr. Swapnil Jangam HDFC Overnight Fund, HDFC NIFTY 1D Rate Liquid ETF - Growth Mr. Swapnil Jangam Mr. Swapnil Jangam and Mr. Rohan Pillai * Mr. Dhruv Muchhal is the dedicated Fund Manager for Overseas Investments.
Powered by Capital Market - Live News
HDFC Mutual Fund announces change in Key Personnel
HDFC Mutual Fund has announced Mr. Anupam Gupta has been appointed as Senior Equity Analyst of HDFC Asset Management Company Limited ('HDFC AMC') with effect from September 23, 2025 and is designated as a Key Personnel of HDFC AMC.Details of Mr. Anupam Gupta
Age: 44 years
Designation: Senior Equity Analyst
Qualification: B.E. in Mechanical Engineering (NIT, Bhopal) PGDBM (IIM Lucknow) CFA (CFA Institute)
Powered by Capital Market - Live News
HDFC MF announces Income Distribution cum capital withdrawal (IDCW) under its schemes
HDFC Mutual Fund has announced 25 September 2025 as the record date for declaration of IDCW in the following schemes. The proposed IDCW on the face value of Rs 10 per unit will be:HDFC Hybrid Equity Fund:
Regular Plan ' IDCW: 0.250
Direct Plan ' IDCW: 0.250
HDFC Equity Savings Fund:
Regular Plan ' IDCW: 0.220
Direct Plan ' IDCW: 0.220
HDFC Balanced Advantage Fund:
Regular Plan ' IDCW: 0.250
Direct Plan ' IDCW: 0.250
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
14 September 2023
Total AUM (Cr)
₹1896.11
HDFC Pharma and Healthcare Fund - Direct (G) is an Sectoral / Thematic-oriented fund from the renowned AMC, HDFC Mutual Fund. Launched in 14 September 2023, this fund is managed by Nikhil Mathur. With assets under management (AUM) worth ₹1,896.11 (Cr), as of 14 October 2025, HDFC Pharma and Healthcare Fund - Direct (G) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 32.45% since its launch.
The current NAV of HDFC Pharma and Healthcare Fund - Direct (G) is ₹17.56, as on 14 October 2025. The fund's benchmark index is BSE Healthcare TRI. You can invest in HDFC Pharma and Healthcare Fund - Direct (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹100 while the minimum lumpsum investment is ₹100.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
In respect of each purchase/Switch-in of units, an Exit load of 1% is payable if units are redeemed/switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched-out after 30 days from the date of allotment. The fund has generated undefined% and undefined% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 99.01% in Equity, 1.05% in Debt and -0.06% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 77.83% in Pharmaceuticals & Biotech, 19.55% in Healthcare Services, 1.15% in Healthcare Equipment & Su, 1.03% in Debt, 0.36% in Insurance